Arena Pharmaceuticals, Inc is a biotechnology business based in the US. Arena Pharmaceuticals shares (ARNA) are listed on the NASDAQ and all prices are listed in US Dollars. Arena Pharmaceuticals employs 363 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Arena Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ARNA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- ARNA shares summary
- Compare share dealing platforms
- Is ARNA stock a buy or sell?
- Stock performance over time
- Can I short ARNA shares?
- Are ARNA shares over-valued?
- Arena Pharmaceuticals's financials
- How volatile are ARNA shares?
- Does Arena Pharmaceuticals pay a dividend?
- Have ARNA shares ever split?
- Other common questions
Arena Pharmaceuticals stock price (NASDAQ: ARNA)Use our graph to track the performance of ARNA stocks over time.
Arena Pharmaceuticals shares at a glance
|Latest market close||$61.11|
|52-week range||$59.55 - $90.19|
|50-day moving average||$66.38|
|200-day moving average||$70.56|
|Wall St. target price||$96.47|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$10.84|
Buy Arena Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Arena Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arena Pharmaceuticals price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||-12.61%|
|3 months (2021-04-29)||-10.91%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Is Arena Pharmaceuticals under- or over-valued?
Valuing Arena Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arena Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Arena Pharmaceuticals's PEG ratio
Arena Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.46. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Arena Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Arena Pharmaceuticals's EBITDA
Arena Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $549.8 million.
The EBITDA is a measure of a Arena Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Arena Pharmaceuticals financials
|Gross profit TTM||$-323,421,000|
|Return on assets TTM||-24.96%|
|Return on equity TTM||-40.78%|
|Market capitalisation||$3.9 billion|
TTM: trailing 12 months
Shorting Arena Pharmaceuticals shares
There are currently 3.4 million Arena Pharmaceuticals shares held short by investors – that's known as Arena Pharmaceuticals's "short interest". This figure is 7.1% up from 3.2 million last month.
There are a few different ways that this level of interest in shorting Arena Pharmaceuticals shares can be evaluated.
Arena Pharmaceuticals's "short interest ratio" (SIR)
Arena Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arena Pharmaceuticals shares currently shorted divided by the average quantity of Arena Pharmaceuticals shares traded daily (recently around 473310.20689655). Arena Pharmaceuticals's SIR currently stands at 7.25. In other words for every 100,000 Arena Pharmaceuticals shares traded daily on the market, roughly 7250 shares are currently held short.
However Arena Pharmaceuticals's short interest can also be evaluated against the total number of Arena Pharmaceuticals shares, or, against the total number of tradable Arena Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arena Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Arena Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0607% of the tradable shares (for every 100,000 tradable Arena Pharmaceuticals shares, roughly 61 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arena Pharmaceuticals.
Find out more about how you can short Arena Pharmaceuticals stock.
Arena Pharmaceuticals share dividends
We're not expecting Arena Pharmaceuticals to pay a dividend over the next 12 months.
Have Arena Pharmaceuticals's shares ever split?
Arena Pharmaceuticals's shares were split on a 1:10 basis on 18 June 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arena Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arena Pharmaceuticals shares which in turn could have impacted Arena Pharmaceuticals's share price.
Arena Pharmaceuticals share price volatility
Over the last 12 months, Arena Pharmaceuticals's shares have ranged in value from as little as $59.55 up to $90.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arena Pharmaceuticals's is 0.5267. This would suggest that Arena Pharmaceuticals's shares are less volatile than average (for this exchange).
Arena Pharmaceuticals overview
Arena Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co. , Ltd. and Eisai Inc.
Stocks similar to Arena Pharmaceuticals
Arena Pharmaceuticals in the news
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Arena Pharma In-Licenses Aristea's CXCR2 Antagonist For Immune-Mediated Inflammatory Diseases
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
Frequently asked questionsWhat percentage of Arena Pharmaceuticals is owned by insiders or institutions?
Currently 0.27% of Arena Pharmaceuticals shares are held by insiders and 95.155% by institutions. How many people work for Arena Pharmaceuticals?
Latest data suggests 363 work at Arena Pharmaceuticals. When does the fiscal year end for Arena Pharmaceuticals?
Arena Pharmaceuticals's fiscal year ends in December. Where is Arena Pharmaceuticals based?
Arena Pharmaceuticals's address is: 136 Heber Avenue, Park City, UT, United States, 84060 What is Arena Pharmaceuticals's ISIN number?
Arena Pharmaceuticals's international securities identification number is: US0400476075 What is Arena Pharmaceuticals's CUSIP number?
Arena Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 040047102
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert